Rekvina Labs Ltd Financial Ratios
VINRKLB · Healthcare · Current price ₹62.1
P/E ratio
-187.9x
P/B ratio
16.8x
ROE
20.7%
ROCE
20.7%
Debt / Equity
—
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | -187.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 16.8x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 20.7% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 20.7% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | — | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Rekvina Labs Ltd's latest numbers.
Rekvina Labs Ltd profitability
Rekvina Labs Ltd generates a return on equity of 20.7% and a return on capital employed of 20.7%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of n/a and a P/E of -187.9x, Rekvina Labs Ltd is conservatively financed. Our overall business-quality score for the company is 5.3 / 10.
Understand the ratios
More on Rekvina Labs Ltd
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.